A Phase Ib Study of the CCR2 Inhibitor PF-04136309 in Combination with FOLFIRINOX Chemotherapy for Patients with Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma. Here, CCR2 is linked to pancreatic ductal adenocarcinoma.